The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 17, 2023

Filed:

Jul. 25, 2022
Applicant:

Arbutus Biopharma Corporation, Vancouver, CA;

Inventors:

Ed Yaworski, Maple Ridge, CA;

Stephen Reid, Surrey, CA;

James Heyes, Vancouver, CA;

Adam Judge, Vancouver, CA;

Ian MacLachlan, Mission, CA;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07H 21/02 (2006.01); A61K 47/44 (2017.01); A61K 9/00 (2006.01); A61K 9/127 (2006.01); A61K 31/713 (2006.01); C12N 15/11 (2006.01); C12N 15/88 (2006.01); A61K 47/54 (2017.01); C12N 15/113 (2010.01);
U.S. Cl.
CPC ...
A61K 47/44 (2013.01); A61K 9/0019 (2013.01); A61K 9/1272 (2013.01); A61K 31/713 (2013.01); A61K 47/543 (2017.08); C12N 15/111 (2013.01); C12N 15/1137 (2013.01); C12N 15/88 (2013.01); C12N 2310/14 (2013.01); C12N 2310/321 (2013.01); C12N 2310/344 (2013.01); C12N 2320/30 (2013.01); C12N 2320/32 (2013.01);
Abstract

The present invention provides novel, serum-stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides serum-stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (e.g., one or more interfering RNA molecules), methods of making the SNALP, and methods of delivering and/or administering the SNALP (e.g., for the treatment of cancer). In particular embodiments, the present invention provides tumor-directed lipid particles that preferentially target solid tumors. The tumor-directed formulations of the present invention are capable of preferentially delivering a payload such as a nucleic acid to cells of solid tumors compared to non-cancerous cells.


Find Patent Forward Citations

Loading…